INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

Group 1 - Integra LifeSciences Holdings Corporation is under investigation for potential securities fraud and unlawful business practices involving its officers and directors [1] - The company reported a first-quarter 2025 earnings per diluted share of -$0.33, a decline from -$0.04 per diluted share in the previous year [3] - Integra's full-year earnings guidance and second-quarter revenue outlook significantly missed consensus estimates, with reported declines in its Neurosurgery and Tissue Technologies businesses due to inventory issues and slower ordering patterns [3] Group 2 - Following the financial results announcement, Integra's stock price dropped by $3.57 per share, or 21.19$13.28 per share on May 5, 2025 [4]